Analysis of the content of the drug instructions for pirtobrutinib

Pirtobrutinib is a new generation, non-covalent Bruton's tyrosine kinase (BTK) inhibitor used to treat certain types of Bcell malignant tumors, including chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Compared with traditional BTK inhibitors, pitobrutinib has obvious advantages in overcoming resistance mutations and improving target selectivity. This article will combine the core content of the drug instructions to comprehensively analyze pitobrutinib from five aspects: indications, usage and dosage, pharmacological mechanism, adverse reactions and precautions.

First of all, indications are an important basis for the clinical application of pitobrutinib. According to the drug instructions, the drug is mainly used to treat patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least two treatment regimens in the past, as well as patients with existing BTKInhibitor-resistant or intolerant chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients. It should be emphasized that the scope of indications for pitobrutinib is still expanding, and it is also in clinical trials in other types of non-Hodgkin lymphoma and solid tumors.

In terms of usage and dosage, the standard dosage recommended in the instructions is 200 mg once a dayorally. Patients should try to take the medicine at a fixed time every day, and can take it with food or on an empty stomach. The medicine is in the form of oral tablets or capsules. The tablets should be swallowed whole and should not be broken or chewed. In addition, if the patient misses a dose, it should be taken as soon as possible within 12 hours. If it exceeds 12 hours, it should be skipped. Double doses should not be taken. Generally, there is no need to adjust the dose for patients with mild liver and kidney function impairment, but whether it is suitable for patients with severe liver function impairment requires a doctor's evaluation.

From the perspective of pharmacological mechanism, as a non-covalent, reversible BTK inhibitor, pitobrutinib is unique in that it can effectively bind BTK pan>Regardless of the presence or absence of the C481 mutation (which is a common cause of resistance to first-generation BTK inhibitors). By blocking the B cell receptor (BCR) signaling pathway, pitobrutinib inhibits tumorsBCell proliferation and survival. Compared with first-generation covalent inhibitors (such as ibrutinib), pitobrutinib is more selective for BTK and less inhibitory to other tyrosine kinases, so it has better safety and tolerability in theory.

In terms of adverse reactions, although pitobrutinib was generally well tolerated, some patients still experienced adverse events during treatment. According to clinical data, the more common adverse reactions include fatigue, diarrhea, nausea, cold-like symptoms, dizziness, myalgia and rash. Serious adverse reactions may include infection, thrombocytopenia, neutropenia, and abnormal heart rhythm. Therefore, patients should regularly monitor blood routine, liver and kidney function and other indicators while taking medication. Once an abnormality is discovered, the medication regimen should be adjusted according to the doctor's recommendations or necessary symptomatic treatment should be carried out.

Finally, in terms of precautions for use, the instructions specifically point out that pitobrutinib may interact with CYP3A enzyme-related drugs. Strong CYP3A inhibitors (such as ketoconazole) or inducers (such as rifampicin) may affect its plasma concentration, so caution is required when used together. In addition, female patients should take effective contraceptive measures during the medication and for a period of time after stopping the medication, because animal experiments show that pitobrutinib may have potential risks to the fetus.

Reference materials:https://go.drugbank.com/drugs/DB17472